in this issue
EnviroTech :: Biotech
KaloBios Signs Research and Commercial Agreement with BioWa and Lonza
12:09 AM MST | February 8, 2011 | Deepti Ramesh
Lonza says that biopharmaceutical company KaloBios Pharmaceuticals (South San Francisco, CA) has signed a research and commercial agreement with biotech company BioWa (Princeton, NJ), a subsidiary of Kyowa Hakko Kirin (Tokyo), and Lonza, to use their Potelligent CHOK1SV cell line for the development and production of KaloBios’ Humaneered antibodies. Potelligent CHOK1SV is a new host cell line for manufacturing recombinant antibodies that combines BioWa’s engineered glycosylation Potelligent technology with Lonza’s proprietary GS Gene Expression...
This information is only available to Chemical Week subscribers.
Forgot your user ID or password?
Not an IHS Chemical Week member yet?
Here's why you should be:
100% Satisfaction Guarantee